470 related articles for article (PubMed ID: 21320275)
1. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma.
Messer J; Shariat SF; Brien JC; Herman MP; Ng CK; Scherr DS; Scoll B; Uzzo RG; Wille M; Eggener SE; Steinberg G; Terrell JD; Lucas SM; Lotan Y; Boorjian SA; Raman JD
BJU Int; 2011 Sep; 108(5):701-5. PubMed ID: 21320275
[TBL] [Abstract][Full Text] [Related]
2. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.
Messer JC; Terrell JD; Herman MP; Ng CK; Scherr DS; Scoll B; Boorjian SA; Uzzo RG; Wille M; Eggener SE; Lucas SM; Lotan Y; Shariat SF; Raman JD
Urol Oncol; 2013 Aug; 31(6):904-8. PubMed ID: 21906967
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
[TBL] [Abstract][Full Text] [Related]
5. Does urinary cytology have a role in haematuria investigations?
Tan WS; Sarpong R; Khetrapal P; Rodney S; Mostafid H; Cresswell J; Watson D; Rane A; Hicks J; Hellawell G; Davies M; Srirangam SJ; Dawson L; Payne D; Williams N; Brew-Graves C; Feber A; Kelly JD;
BJU Int; 2019 Jan; 123(1):74-81. PubMed ID: 30003675
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]).
van der Aa MN; Zwarthoff EC; Steyerberg EW; Boogaard MW; Nijsen Y; van der Keur KA; van Exsel AJ; Kirkels WJ; Bangma C; van der Kwast TH
Eur Urol; 2009 Mar; 55(3):659-67. PubMed ID: 18501499
[TBL] [Abstract][Full Text] [Related]
9. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
10. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
11. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K
J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
[TBL] [Abstract][Full Text] [Related]
12. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
13. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
14. Urine cytology in bladder tumors.
Zein TA; Milad MF
Int Surg; 1991; 76(1):52-4. PubMed ID: 2045253
[TBL] [Abstract][Full Text] [Related]
15. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
17. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.
Karakiewicz PI; Benayoun S; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Marberger MJ; Shariat SF
BJU Int; 2006 May; 97(5):997-1001. PubMed ID: 16542342
[TBL] [Abstract][Full Text] [Related]
18. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy.
Dutta SC; Smith JA; Shappell SB; Coffey CS; Chang SS; Cookson MS
J Urol; 2001 Aug; 166(2):490-3. PubMed ID: 11458053
[TBL] [Abstract][Full Text] [Related]
19. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance.
Johannes JR; Nelson E; Bibbo M; Bagley DH
J Urol; 2010 Sep; 184(3):879-82. PubMed ID: 20643443
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]